Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Graft Manipulation

Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index

Bone Marrow Transplantation volume 51, pages 955–960 (2016)Cite this article

Subjects

Abstract

Comparisons of hematopoietic stem cell transplantation (HSCT) methods in retrospective studies are often hampered by the heterogeneity of comparison groups. The refined disease risk index (DRI) is a potentially interesting tool to compare HSCT protocols as it is based on the disease type and burden at transplant and stratifies patients into four prognostic groups for overall survival (OS). We included 265 patients with partial T-cell-depleted graft (TDEP) and 163 non-TDEP patients in a retrospective study and compared outcomes following stratification using the refined DRI. The 2-year OS rate for TDEP patients was 81.6, 60.9 and 43.3% for the low-, intermediate- and high-risk groups, respectively (P<0.001). For non-TDEP patients, the 2-year OS rate was 62.9, 48.8, 44.2 and 7.6% for the low-, intermediate-, high- and very-high-risk groups, respectively (P<0.001). There was no significant difference when comparing OS between TDEP and non-TDEP for the low-, intermediate- and high-risk groups, but TDEP patients had less acute GvHD grades II–IV. In conclusion, we confirm that the refined DRI is a valuable tool to compare the outcomes of different HSCT protocols. We demonstrate also that TDEP did not impact on the outcome of HSCT, but it did reduce the incidence of acute GvHD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Copelan EA . Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354: 1813–1826.

    Article  CAS  PubMed  Google Scholar 

  2. Armand P, Gibson CJ, Cutler C, Ho VT, Koreth J, Alyea EP et al. A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood 2012; 120: 905–913.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME et al. Validation and refinement of the disease risk index for allogeneic stem cell transplantation. Blood 2014; 123: 3664–3671.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR . CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA 1999; 96: 8639–8644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bleakley M, Riddell SR . Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer 2004; 4: 371–380.

    Article  CAS  PubMed  Google Scholar 

  6. Barrett AJ, Malkovska V . Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br J Haematol 1996; 93: 754–761.

    Article  CAS  PubMed  Google Scholar 

  7. Welniak LA, Blazar BR, Murphy WJ . Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007; 25: 139–170.

    Article  CAS  PubMed  Google Scholar 

  8. Beauverd Y, Roosnek E, Tirefort Y, Nagy-Hulliger M, Bernimoulin M, Tsopra O et al. Validation of the disease risk index for outcome of patients undergoing allogeneic hematopoietic stem cell transplantation after T cell depletion. Biol Blood Marrow Transplant 2014; 20: 1322–1328.

    Article  PubMed  Google Scholar 

  9. Chalandon Y, Roosnek E, Mermillod B, Waelchli L, Helg C, Chapuis B . Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biol Blood Marrow Transplant 2006; 12: 102–110.

    Article  PubMed  Google Scholar 

  10. Chakrabarti S, MacDonald D, Hale G, Holder K, Turner V, Czarnecka H et al. T-cell depletion with Campath-1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival. Br J Haematol 2003; 121: 109–118.

    Article  PubMed  Google Scholar 

  11. Armand P, Deeg HJ, Kim HT, Lee H, Armistead P, de Lima M et al. Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant 2010; 45: 877–885.

    Article  CAS  PubMed  Google Scholar 

  12. Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR et al. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant 2012; 18: 280–288.

    Article  PubMed  Google Scholar 

  13. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  14. Fine J, Gray R . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  15. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912–2919.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de Witte T et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715–4726.

    Article  PubMed  Google Scholar 

  17. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY et al. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 2002; 100: 406–414.

    Article  CAS  PubMed  Google Scholar 

  18. Levrat E, Roosnek E, Masouridi S, Mohty B, Ansari M, Villard J et al. Very long term stability of mixed chimerism after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Bone Marrow Res 2015; 2015: 176526.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sorror M, Storer B, Sandmaier BM, Maloney DG, Chauncey TR, Langston A et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 2008; 112: 1992–2001.

    Article  PubMed  Google Scholar 

  20. Remberger M, Ackefors M, Berglund S, Blennow O, Dahllof G, Dlugosz A et al. Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study. Biol Blood Marrow Transplant 2011; 17: 1688–1697.

    Article  PubMed  Google Scholar 

  21. Hahn T, McCarthy PL Jr., Hassebroek A, Bredeson C, Gajewski JL, Hale GA et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. J Clin Oncol 2013; 31: 2437–2449.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Stem Cell Transplant Unit, Geneva’s University Hospitals, Geneva, Switzerland

    Y Beauverd, E Roosnek, Y Tirefort, C Dantin, O Tsopra, S Masouridi-Levrat & Y Chalandon

  2. Department of Pediatrics, Onco-Hematology unit, Geneva’s University Hospitals, Geneva, Switzerland

    M Ansari

Authors
  1. Y Beauverd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Roosnek
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Y Tirefort
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Dantin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Ansari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. O Tsopra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Masouridi-Levrat
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Y Chalandon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Y Chalandon.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Author contributions

YB and YC designed the study and analyzed the data. YT, CD, MA, OT and SML contributed data and reviewed the manuscript. YB, ER and YC wrote the manuscript. All authors read and approved the final manuscript.

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beauverd, Y., Roosnek, E., Tirefort, Y. et al. Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index. Bone Marrow Transplant 51, 955–960 (2016). https://doi.org/10.1038/bmt.2016.34

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.34

This article is cited by

Search

Advanced search

Quick links